I-Mab logo
I-Mab IMAB

Quarterly report 2025-Q2
added 02-21-2026

report update icon

I-Mab Balance Sheet 2011-2026 | IMAB

Annual Balance Sheet I-Mab

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -1.06 B -1.61 B -94.9 M - - - - - -

Long Term Debt

- - - - - 68.2 M 67 M 114 M - - - - - -

Long Term Debt Current

- - - - 8.06 M 6.81 M - - - - - - - -

Total Non Current Liabilities

- - - - 131 M 79.6 M 2.98 B 1.13 B - - - - - -

Total Current Liabilities

- - - - 576 M 588 M 346 M - - - - - - -

Total Liabilities

- - - - 707 M 668 M 416 M 1.33 B - - - - - -

Deferred Revenue

- - - - - 563 K 14.2 M 15.8 M - - - - - -

Retained Earnings

- -8.33 B -6.86 B -4.35 B -2.02 B -2.49 B -1.01 B -358 M - - - - - -

Total Assets

- - - - 6.33 B 1.74 B 2.38 B 1.03 B - - - - - -

Cash and Cash Equivalents

- - - - 4.76 B 1.14 B 1.68 B 413 M - - - - - -

Book Value

- - - - 5.63 B 1.07 B 1.96 B -300 M - - - - - -

Total Shareholders Equity

- 1.72 B 2.91 B 4.56 B 5.63 B -2.03 B -955 M -300 M - - - - - -

All numbers in CNY currency

Quarterly Balance Sheet I-Mab

2025-Q2 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - 81.8 M - - - 5.54 M 5.18 M - - 7.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 895 M 1.16 B - 975 M - 1.04 B - - - 707 M 556 M - - 668 M - - - 416 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - 14.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -8.33 B -6.86 B - -5.4 B - -4.35 B - - - -2.02 B -3.06 B - - -2.49 B - - - -1.01 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 2.61 B 4.07 B - 4.99 B - 5.6 B - - - 6.33 B 4.3 B - - 1.74 B - - - 2.38 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - - 3.52 B - - - 4.76 B 2.96 B - - 1.14 B 1.28 B - - 1.59 B - - - 413 M - - - 64.1 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - 1.07 B - - - 1.96 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - -2.03 B -1.63 B - - -955 M - - - -300 M - - - -14.5 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Balance Sheet is a fundamental financial report of I-Mab, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 2.44 % $ 429 M britainBritain
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.81 1.73 % $ 260 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Adagene Adagene
ADAG
$ 3.26 0.62 % $ 183 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.28 -2.62 % $ 7.89 B australiaAustralia
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.81 -9.28 % $ 27.9 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.29 % $ 4.31 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 0.88 -1.43 % $ 442 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 224.42 -2.52 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.13 0.12 % $ 352 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.36 2.27 % $ 14.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Codexis Codexis
CDXS
$ 1.17 -0.85 % $ 85.9 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.12 -0.28 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.49 -0.75 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany